Careful adjustment of Epo non-viral gene therapy for β-thalassemic anaemia treatment

BACKGROUND: In situ production of a secreted therapeutic protein is one of the major gene therapy applications. Nevertheless, the plasmatic secretion peak of transgenic protein may be deleterious in many gene therapy applications including Epo gene therapy. Epo gene transfer appears to be a promisin...

Descripción completa

Detalles Bibliográficos
Autores principales: Fabre, Emmanuelle E, Bigey, Pascal, Beuzard, Yves, Scherman, Daniel, Payen, Emmanuel
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2008
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2276190/
https://www.ncbi.nlm.nih.gov/pubmed/18334017
http://dx.doi.org/10.1186/1479-0556-6-10

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2276190/
https://www.ncbi.nlm.nih.gov/pubmed/18334017
http://dx.doi.org/10.1186/1479-0556-6-10

Ejemplares similares